{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:25:55Z","timestamp":1792790755797,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI168408-01A1"],"award-info":[{"award-number":["R01 AI168408-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI168408-01A1"],"award-info":[{"award-number":["R01 AI168408-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI168408-01A1"],"award-info":[{"award-number":["R01 AI168408-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI168408-01A1"],"award-info":[{"award-number":["R01 AI168408-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI168408-01A1"],"award-info":[{"award-number":["R01 AI168408-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI168408-01A1"],"award-info":[{"award-number":["R01 AI168408-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Science Foundation","award":["DGE-2039655"],"award-info":[{"award-number":["DGE-2039655"]}]},{"name":"National Science Foundation","award":["DGE-2039655"],"award-info":[{"award-number":["DGE-2039655"]}]},{"name":"National Institutes of Health, United States","award":["T32 EB021962"],"award-info":[{"award-number":["T32 EB021962"]}],"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-025-01276-w","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T14:39:22Z","timestamp":1762180762000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inverted H1 hemagglutinin nanoparticle vaccines protect mice against challenges with human H1N1 and bovine H5N1 influenza viruses"],"prefix":"10.1038","volume":"10","author":[{"given":"Asim","family":"Biswas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donguk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amie J.","family":"Eisfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Augustine","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hunter","family":"Hammond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Sangappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassanein H.","family":"Abozeid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi S.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"1276_CR1","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1093\/aje\/kwaa196","volume":"190","author":"V Cozza","year":"2020","unstructured":"Cozza, V. et al. Global seasonal influenza mortality estimates: a comparison of 3 different approaches. Am. J. Epidemiol. 190, 718\u2013727 (2020).","journal-title":"Am. J. Epidemiol."},{"key":"1276_CR2","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2243","volume":"32","author":"Y-H Kim","year":"2022","unstructured":"Kim, Y.-H., Hong, K.-J., Kim, H. & Nam, J.-H. Influenza vaccines: past, present, and future. Rev. Med. Virol. 32, e2243 (2022).","journal-title":"Rev. Med. Virol."},{"key":"1276_CR3","doi-asserted-by":"publisher","first-page":"5496","DOI":"10.1016\/j.vaccine.2014.07.074","volume":"32","author":"B Buckland","year":"2014","unstructured":"Buckland, B. et al. Technology transfer and scale-up of the Flublok\u00ae recombinant hemagglutinin (HA) influenza vaccine manufacturing process. Vaccine 32, 5496\u20135502 (2014).","journal-title":"Vaccine"},{"key":"1276_CR4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40265-013-0103-6","volume":"73","author":"LPH Yang","year":"2013","unstructured":"Yang, L. P. H. Recombinant trivalent influenza vaccine (Flublok\u00ae): a review of its use in the prevention of seasonal influenza in adults. Drugs 73, 1357\u20131366 (2013).","journal-title":"Drugs"},{"key":"1276_CR5","doi-asserted-by":"publisher","first-page":"e25797","DOI":"10.1371\/journal.pone.0025797","volume":"6","author":"MA Moody","year":"2011","unstructured":"Moody, M. A. et al. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. PLoS ONE. 6, e25797 (2011).","journal-title":"PLoS ONE."},{"key":"1276_CR6","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nature06890","volume":"453","author":"J Wrammert","year":"2008","unstructured":"Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667\u2013671 (2008).","journal-title":"Nature"},{"key":"1276_CR7","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1128\/JVI.03509-12","volume":"87","author":"I Margine","year":"2013","unstructured":"Margine, I. et al. H3N2 influenza virus infection induces broadly reactive hemagglutinin stalk antibodies in humans and mice. J. Virol. 87, 4728\u20134737 (2013).","journal-title":"J. Virol."},{"key":"1276_CR8","doi-asserted-by":"publisher","first-page":"20248","DOI":"10.1073\/pnas.1320524110","volume":"110","author":"NS Heaton","year":"2013","unstructured":"Heaton, N. S., Sachs, D., Chen, C.-J., Hai, R. & Palese, P. Genome-wide mutagenesis of influenza virus reveals unique plasticity of the hemagglutinin and NS1 proteins. Proc. Natl Acad. Sci. USA 110, 20248\u201320253 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1276_CR9","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.03300","volume":"3","author":"B Thyagarajan","year":"2014","unstructured":"Thyagarajan, B. & Bloom, J. D. The inherent mutational tolerance and antigenic evolvability of influenza hemagglutinin. eLife 3, e03300 (2014).","journal-title":"eLife"},{"key":"1276_CR10","doi-asserted-by":"publisher","first-page":"e80034","DOI":"10.1371\/journal.pone.0080034","volume":"8","author":"B Brandenburg","year":"2013","unstructured":"Brandenburg, B. et al. Mechanisms of hemagglutinin targeted influenza virus neutralization. PLoS ONE 8, e80034 (2013).","journal-title":"PLoS ONE"},{"key":"1276_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-28706-1","volume":"8","author":"E Kirkpatrick","year":"2018","unstructured":"Kirkpatrick, E., Qiu, X., Wilson, P. C., Bahl, J. & Krammer, F. The influenza virus hemagglutinin head evolves faster than the stalk domain. Sci. Rep. 8, 10432 (2018).","journal-title":"Sci. Rep."},{"key":"1276_CR12","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-024-07766-6","volume":"633","author":"AJ Eisfeld","year":"2024","unstructured":"Eisfeld, A. J. et al. Pathogenicity and transmissibility of bovine H5N1 influenza virus. Nature 633, 426\u2013432 (2024).","journal-title":"Nature"},{"key":"1276_CR13","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41586-024-08254-7","volume":"636","author":"C Gu","year":"2024","unstructured":"Gu, C. et al. A human isolate of bovine H5N1 is transmissible and lethal in animal models. Nature 636, 711\u2013718 (2024).","journal-title":"Nature"},{"key":"1276_CR14","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1056\/NEJMc2405371","volume":"390","author":"TM Uyeki","year":"2024","unstructured":"Uyeki, T. M. et al. Highly pathogenic avian influenza A(H5N1) virus infection in a dairy farm worker. N. Engl. J. Med. 390, 2028\u20132029 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1276_CR15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1126\/science.adt0180","volume":"386","author":"T-H Lin","year":"2024","unstructured":"Lin, T.-H. et al. A single mutation in bovine influenza H5N1 hemagglutinin switches specificity to human receptors. Science 386, 1128\u20131134 (2024).","journal-title":"Science"},{"key":"1276_CR16","doi-asserted-by":"publisher","first-page":"e3002916","DOI":"10.1371\/journal.pbio.3002916","volume":"22","author":"B Dadonaite","year":"2024","unstructured":"Dadonaite, B. et al. Deep mutational scanning of H5 hemagglutinin to inform influenza virus surveillance. PLoS Biol. 22, e3002916 (2024).","journal-title":"PLoS Biol."},{"key":"1276_CR17","doi-asserted-by":"publisher","first-page":"e03617","DOI":"10.1128\/mBio.03617-20","volume":"12","author":"EK Roubidoux","year":"2021","unstructured":"Roubidoux, E. K. et al. Mutations in the hemagglutinin stalk domain do not permit escape from a protective, stalk-based vaccine-induced immune response in the mouse model. mBio, 12, e03617\u2013e03620 (2021).","journal-title":"mBio"},{"key":"1276_CR18","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.coviro.2012.02.005","volume":"2","author":"DC Ekiert","year":"2012","unstructured":"Ekiert, D. C. & Wilson, I. A. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr. Opin. Virol. 2, 134\u2013141 (2012).","journal-title":"Curr. Opin. Virol."},{"key":"1276_CR19","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1126\/science.1171491","volume":"324","author":"DC Ekiert","year":"2009","unstructured":"Ekiert, D. C. et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324, 246\u2013251 (2009).","journal-title":"Science"},{"key":"1276_CR20","doi-asserted-by":"publisher","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","volume":"3","author":"M Throsby","year":"2008","unstructured":"Throsby, M. et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3, e3942 (2008).","journal-title":"PLoS ONE"},{"key":"1276_CR21","doi-asserted-by":"publisher","first-page":"6179","DOI":"10.1128\/JVI.00469-12","volume":"86","author":"Gene Tan","year":"2012","unstructured":"Tan, G. ene et al. A Pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J. Virol. 86, 6179\u20136188 (2012).","journal-title":"J. Virol."},{"key":"1276_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03665-3","volume":"9","author":"MB Doud","year":"2018","unstructured":"Doud, M. B., Lee, J. M. & Bloom, J. D. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nat. Commun. 9, 1386 (2018).","journal-title":"Nat. Commun."},{"key":"1276_CR23","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1126\/science.aac7263","volume":"349","author":"A Impagliazzo","year":"2015","unstructured":"Impagliazzo, A. et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. Science 349, 1301\u20131306 (2015).","journal-title":"Science"},{"key":"1276_CR24","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1073\/pnas.1308701110","volume":"111","author":"Y Lu","year":"2014","unstructured":"Lu, Y., Welsh, J. P. & Swartz, J. R. Production and stabilization of the trimeric influenza hemagglutinin stem domain for potentially broadly protective influenza vaccines. Proc. Natl Acad. Sci. USA 111, 125\u2013130 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1276_CR25","doi-asserted-by":"publisher","first-page":"E2514","DOI":"10.1073\/pnas.1402766111","volume":"111","author":"VVA Mallajosyula","year":"2014","unstructured":"Mallajosyula, V. V. A. et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl Acad. Sci. USA 111, E2514\u2013E2523 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1276_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep22666","volume":"6","author":"SA Valkenburg","year":"2016","unstructured":"Valkenburg, S. A. et al. Stalking influenza by vaccination with pre-fusion headless HA mini-stem. Sci. Rep. 6, 22666 (2016).","journal-title":"Sci. Rep."},{"key":"1276_CR27","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nm.3927","volume":"21","author":"HM Yassine","year":"2015","unstructured":"Yassine, H. M. et al. Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection. Nat. Med. 21, 1065\u20131070 (2015).","journal-title":"Nat. Med."},{"key":"1276_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-02725-4","volume":"9","author":"L Deng","year":"2018","unstructured":"Deng, L. et al. Double-layered protein nanoparticles induce broad protection against divergent influenza A viruses. Nat. Commun. 9, 359 (2018).","journal-title":"Nat. Commun."},{"key":"1276_CR29","doi-asserted-by":"publisher","unstructured":"Corbett, K. S. et al. Design of nanoparticulate group 2 influenza virus hemagglutinin stem antigens that activate unmutated ancestor B cell receptors of broadly neutralizing antibody lineages. mBio, https:\/\/doi.org\/10.1128\/mbio.02810-18 (2019).","DOI":"10.1128\/mbio.02810-18"},{"key":"1276_CR30","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1016\/j.immuni.2022.10.015","volume":"55","author":"SM Moin","year":"2022","unstructured":"Moin, S. M. et al. Co-immunization with hemagglutinin stem immunogens elicits cross-group neutralizing antibodies and broad protection against influenza A viruses. Immunity 55, 2405\u20132418.e2407 (2022).","journal-title":"Immunity"},{"key":"1276_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-017-0036-2","volume":"2","author":"TC Sutton","year":"2017","unstructured":"Sutton, T. C. et al. Protective efficacy of influenza group 2 hemagglutinin stem-fragment immunogen vaccines. npj Vaccines 2, 35 (2017).","journal-title":"npj Vaccines"},{"key":"1276_CR32","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.ade4790","volume":"15","author":"AT Widge","year":"2023","unstructured":"Widge, A. T. et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med. 15, eade4790 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1276_CR33","doi-asserted-by":"publisher","first-page":"6542","DOI":"10.1128\/JVI.00641-13","volume":"87","author":"F Krammer","year":"2013","unstructured":"Krammer, F., Pica, N., Hai, R., Margine, I. & Palese, P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J. Virol. 87, 6542\u20136550 (2013).","journal-title":"J. Virol."},{"key":"1276_CR34","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med. 27, 106\u2013114 (2021).","journal-title":"Nat. Med."},{"key":"1276_CR35","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1128\/JVI.02608-13","volume":"88","author":"D Eggink","year":"2014","unstructured":"Eggink, D., Goff, P. H. & Palese, P. Guiding the immune response against influenza virus hemagglutinin toward the conserved stalk domain by hyperglycosylation of the globular head domain. J. Virol. 88, 699\u2013704 (2014).","journal-title":"J. Virol."},{"key":"1276_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/chemistry7010012","volume":"7","author":"D Kim","year":"2025","unstructured":"Kim, D. et al. Tethered antigenic suppression shields the hemagglutinin head domain and refocuses the antibody response to the stalk domain. Chemistry 7, 12 (2025).","journal-title":"Chemistry"},{"key":"1276_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202202729","volume":"12","author":"SJ Frey","year":"2023","unstructured":"Frey, S. J. et al. Nanovaccines displaying the influenza virus hemagglutinin in an inverted orientation elicit an enhanced stalk-directed antibody response. Adv. Healthc. Mater. 12, 2202729 (2023).","journal-title":"Adv. Healthc. Mater."},{"key":"1276_CR38","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1038\/s41589-023-01529-6","volume":"20","author":"D Xu","year":"2024","unstructured":"Xu, D. et al. Vaccine design via antigen reorientation. Nat. Chem. Biol. 20, 1012\u20131021 (2024).","journal-title":"Nat. Chem. Biol."},{"key":"1276_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coviro.2016.03.001","volume":"18","author":"KM Frietze","year":"2016","unstructured":"Frietze, K. M., Peabody, D. S. & Chackerian, B. Engineering virus-like particles as vaccine platforms. Curr. Opin. Virol. 18, 44\u201349 (2016).","journal-title":"Curr. Opin. Virol."},{"key":"1276_CR40","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s42003-021-02128-8","volume":"4","author":"S Chiba","year":"2021","unstructured":"Chiba, S. et al. Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. Commun. Biol. 4, 597 (2021).","journal-title":"Commun. Biol."},{"key":"1276_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202002140","volume":"10","author":"A Castro","year":"2021","unstructured":"Castro, A., Carre\u00f1o, J. M., Duehr, J., Krammer, F. & Kane, R. S. Refocusing the immune response to selected epitopes on a Zika virus protein antigen by nanopatterning. Adv. Healthc. Mater. 10, 2002140 (2021).","journal-title":"Adv. Healthc. Mater."},{"key":"1276_CR42","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/371623a0","volume":"371","author":"K Valeg\u00e5rd","year":"1994","unstructured":"Valeg\u00e5rd, K., Murray, J. B., Stockley, P. G., Stonehouse, N. J. & Liljas, L. Crystal structure of an RNA bacteriophage coat protein\u2013operator complex. Nature 371, 623\u2013626 (1994).","journal-title":"Nature"},{"key":"1276_CR43","doi-asserted-by":"publisher","first-page":"104341","DOI":"10.1016\/j.ebiom.2022.104341","volume":"86","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. Multivalent S2-based vaccines provide broad protection against SARS-CoV-2 variants of concern and pangolin coronaviruses. eBioMedicine 86, 104341 (2022).","journal-title":"eBioMedicine"},{"key":"1276_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-55824-y","volume":"16","author":"PJ Halfmann","year":"2025","unstructured":"Halfmann, P. J. et al. Multivalent S2 subunit vaccines provide broad protection against Clade 1 sarbecoviruses in female mice. Nat. Commun. 16, 462 (2025).","journal-title":"Nat. Commun."},{"key":"1276_CR45","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/ni.3680","volume":"18","author":"D Angeletti","year":"2017","unstructured":"Angeletti, D. et al. Defining B cell immunodominance to viruses. Nat. Immunol. 18, 456\u2013463 (2017).","journal-title":"Nat. Immunol."},{"key":"1276_CR46","doi-asserted-by":"publisher","first-page":"15307","DOI":"10.1039\/C9NR05145G","volume":"11","author":"A Arsiwala","year":"2019","unstructured":"Arsiwala, A. et al. Nanopatterning protein antigens to refocus the immune response. Nanoscale 11, 15307\u201315311 (2019).","journal-title":"Nanoscale"},{"key":"1276_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45495-6","volume":"15","author":"PJ Halfmann","year":"2024","unstructured":"Halfmann, P. J. et al. Broad protection against clade 1 sarbecoviruses after a single immunization with cocktail spike-protein-nanoparticle vaccine. Nat. Commun. 15, 1284 (2024).","journal-title":"Nat. Commun."},{"key":"1276_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jmb.2013.09.016","volume":"426","author":"M Fairhead","year":"2014","unstructured":"Fairhead, M., Krndija, D., Lowe, E. D. & Howarth, M. Plug-and-play pairing via defined divalent streptavidins. J. Mol. Biol. 426, 199\u2013214 (2014).","journal-title":"J. Mol. Biol."},{"key":"1276_CR49","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/nprot.2008.20","volume":"3","author":"M Howarth","year":"2008","unstructured":"Howarth, M. & Ting, A. Y. Imaging proteins in live mammalian cells with biotin ligase and monovalent streptavidin. Nat. Protoc. 3, 534\u2013545 (2008).","journal-title":"Nat. Protoc."},{"key":"1276_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/srep34527","volume":"6","author":"JA Fonseca","year":"2016","unstructured":"Fonseca, J. A. et al. A chimeric protein-based malaria vaccine candidate induces robust T cell responses against Plasmodium vivax MSP119. Sci. Rep. 6, 34527 (2016).","journal-title":"Sci. Rep."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01276-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01276-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01276-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:03:45Z","timestamp":1762185825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01276-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1276"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01276-w","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests: Y.K. has received unrelated funding support from Daiichi Sankyo Pharmaceutical, Toyama Chemical, Tauns Laboratories, Inc., Shionogi & Co., Ltd, Otsuka Pharmaceutical, KM Biologics, Kyoritsu Seiyaku, Shinya Corporation, and Fuji Rebio. Y.K. and G.N. are co-founders of FluGen. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"225"}}